Pfizer Inc. (NYSE:PFE) Given Consensus Rating of "Hold" by Analysts

Last updated on Sunday, June 13, 2021 | 2021 MarketBeat

Pfizer Inc. (NYSE:PFE) has received a consensus rating of "Hold" from the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. Twelve equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $39.73.

Several equities analysts recently issued reports on PFE shares. Barclays lifted their price objective on Pfizer from $37.00 to $40.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 5th. JPMorgan Chase & Co. set a $40.00 price target on Pfizer and gave the stock a "neutral" rating in a report on Monday, May 24th. Berenberg Bank reissued a "neutral" rating and issued a $38.00 price target on shares of Pfizer in a report on Tuesday, March 23rd. Mizuho reissued a "neutral" rating and issued a $42.00 price target on shares of Pfizer in a report on Wednesday, May 12th. Finally, The Goldman Sachs Group set a $45.00 price target on Pfizer and gave the stock a "neutral" rating in a report on Monday, May 24th.

Shares of PFE stock opened at $40.15 on Friday. The business's fifty day moving average price is $38.84. The firm has a market capitalization of $224.75 billion, a PE ratio of 20.48, a PEG ratio of 1.42 and a beta of 0.74. Pfizer has a 1 year low of $31.61 and a 1 year high of $43.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.16 and a current ratio of 1.48.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, May 4th. The biopharmaceutical company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.15. The firm had revenue of $14.58 billion during the quarter, compared to analysts' expectations of $13.41 billion. Pfizer had a return on equity of 24.55% and a net margin of 22.09%. Pfizer's revenue was up 44.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.80 earnings per share. As a group, sell-side analysts anticipate that Pfizer will post 3.69 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 4th. Stockholders of record on Friday, May 7th were given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date was Thursday, May 6th. Pfizer's dividend payout ratio is currently 70.27%.

In other news, SVP Jennifer B. Damico sold 2,500 shares of Pfizer stock in a transaction on Wednesday, May 5th. The stock was sold at an average price of $40.82, for a total value of $102,050.00. Following the completion of the sale, the senior vice president now owns 13,748 shares of the company's stock, valued at $561,193.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.05% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of PFE. Alpha DNA Investment Management LLC purchased a new stake in Pfizer during the fourth quarter valued at about $26,000. Orion Capital Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $29,000. Merrion Investment Management Co LLC acquired a new position in shares of Pfizer during the fourth quarter worth about $30,000. Benjamin Edwards Inc. lifted its stake in shares of Pfizer by 36.5% during the first quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company's stock worth $36,000 after purchasing an additional 267 shares in the last quarter. Finally, EMC Capital Management acquired a new position in shares of Pfizer during the fourth quarter worth about $37,000. 64.22% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.

Featured Article: How Do Mutual Funds Work?

Analyst Recommendations for Pfizer (NYSE:PFE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: What does a neutral rating on stocks mean?


7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future

When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.

The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.

IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.

And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.

But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.

View the "7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.